MedPath

Polyacrylamide Hydrogel Injection Treatment for Anal Incontinence

Phase 4
Completed
Conditions
Anal Incontinence
Registration Number
NCT02550899
Lead Sponsor
Karolinska Institutet
Brief Summary

A randomized study to evaluate the safety and effects of transanal submucosal polyacrylamide hydrogel injection therapy for anal incontinence.

Detailed Description

A prospective randomized study to assess the use of Bulkamid for anal incontinence using three different transanal injection techniques .

Patients with anal incontinence severity Wexner score \>7. Standardised injection treatment at baseline. Clinical status and subjective symptom evaluation (Wexner score and FIQL) at baseline, 2 months, 6 months and 1 year.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • informed consent, anal incontinence with Wexner score >10
Exclusion Criteria
  • ino additional pregnancies, schedule for pelvic organ surgery within 1 year of treatment, current or previous pelvic organ cancer, insulin treated diabetes, inflammatory bowel disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Wexner overall score1 year
Secondary Outcome Measures
NameTimeMethod
FIQL overall score1 year
Adverse events1 year

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.